Abeona Financial Statements From 2010 to 2026

ABEO Stock

USD 5.31 0.06 1.14%

Abeona Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Abeona Therapeutics' valuation are provided below:

Gross Profit

-29.3 M

Profit Margin

205.875

Market Capitalization

284.5 M

Enterprise Value Revenue

253.7366

Revenue

400 K

We have found one hundred twenty available fundamental signals for Abeona Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Abeona Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 20th of January 2026, Market Cap is likely to drop to about 1.8 M. In addition to that, Enterprise Value is likely to grow to about (5.9 M)

Abeona Therapeutics Total Revenue

3.5 Million

Check Abeona Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abeona Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 5.1 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 33.43, Dividend Yield of 6.5 K or PTB Ratio of 5.8. Abeona financial statements analysis is a perfect complement when working with Abeona Therapeutics Valuation or Volatility modules.

Build AI portfolio with Abeona Stock

Check out the analysis of Abeona Therapeutics Correlation against competitors.

To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.

Abeona Therapeutics Balance Sheet

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Total Assets

131.5 M

125.3 M

89.2 M

Slightly volatile

Short and Long Term Debt Total

27.8 M

26.5 M

13.3 M

Slightly volatile

Other Current Liabilities

5.5 M

7.4 M

8.3 M

Pretty Stable

Total Current Liabilities

10.1 M

19.1 M

13.6 M

Slightly volatile

Accounts Payable

2.5 M

4 M

2.7 M

Slightly volatile

Cash

20.4 M

26.9 M

32.7 M

Pretty Stable

Cash And Short Term Investments

118 M

112.4 M

61.8 M

Slightly volatile

Common Stock Total Equity

1.2 M

1.1 M

639.9 K

Slightly volatile

Common Stock Shares Outstanding

49.6 M

47.2 M

10.8 M

Slightly volatile

Liabilities And Stockholders Equity

131.5 M

125.3 M

89.2 M

Slightly volatile

Non Current Liabilities Total

58.3 M

55.6 M

19.7 M

Slightly volatile

Other Stockholder Equity

1 B

985.3 M

550.5 M

Slightly volatile

Total Liabilities

78.4 M

74.6 M

33.9 M

Slightly volatile

Total Current Assets

121.8 M

116 M

64.3 M

Slightly volatile

Common Stock

408.1 K

525.5 K

460.2 K

Slightly volatile

Property Plant And Equipment Net

9.6 M

9.2 M

7 M

Slightly volatile

Non Current Assets Total

17 M

9.3 M

25.4 M

Pretty Stable

Non Currrent Assets Other

82.1 K

86.4 K

252.3 K

Pretty Stable

Property Plant And Equipment Gross

27.7 M

26.4 M

10.7 M

Slightly volatile

Current Deferred Revenue

590.9 K

340.4 K

546.4 K

Very volatile

Other Assets

36.8 K

38.7 K

332.9 K

Very volatile

Property Plant Equipment

13.4 M

12.7 M

7.3 M

Slightly volatile

Other Liabilities

28.8 M

27.4 M

12.6 M

Slightly volatile

Capital Surpluse

518.5 M

773.1 M

500.3 M

Slightly volatile

Short and Long Term Debt

4.6 M

6.8 M

4.6 M

Slightly volatile

Net Invested Capital

74.3 M

56.7 M

121.4 M

Slightly volatile

Net Working Capital

56.4 M

75.8 M

96.5 M

Slightly volatile

Capital Stock

531.1 K

411.3 K

554.2 K

Very volatile

Capital Lease Obligations

5.5 M

3.7 M

7.2 M

Slightly volatile

Long Term Debt Total

1.1 M

1.3 M

1.4 M

Slightly volatile

Abeona Therapeutics Income Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Depreciation And Amortization

1.8 M

3.3 M

2.3 M

Slightly volatile

Selling General Administrative

25.5 M

26.9 M

15.3 M

Slightly volatile

Other Operating Expenses

77.5 M

73.8 M

43.8 M

Slightly volatile

Research Development

41.5 M

39.5 M

22.2 M

Slightly volatile

Total Operating Expenses

74 M

70.5 M

40.2 M

Slightly volatile

Cost Of Revenue

3.2 M

3.3 M

13.2 M

Very volatile

Selling And Marketing Expenses

1.4 M

273.8 M

Slightly volatile

Preferred Stock And Other Adjustments

2.3 M

2.6 M

2.8 M

Slightly volatile

Interest Income

4 M

3.8 M

2.7 M

Slightly volatile

Reconciled Depreciation

4 M

3.3 M

2.5 M

Slightly volatile

Abeona Therapeutics Cash Flow Statement

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Begin Period Cash Flow

19.8 M

17 M

31.7 M

Pretty Stable

Depreciation

1.9 M

3.3 M

2.3 M

Slightly volatile

End Period Cash Flow

20.8 M

27.2 M

33.3 M

Pretty Stable

Stock Based Compensation

8.3 M

6 M

7.3 M

Pretty Stable

Financial Ratios

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Price To Sales Ratio

33.43

35.19

82.5928

Very volatile

Dividend Yield

6.5 K

6.2 K

5.6 K

Slightly volatile

Days Sales Outstanding

278

293

149

Slightly volatile

Stock Based Compensation To Revenue

1.49

1.57

81.4928

Slightly volatile

Capex To Depreciation

0.51

0.76

0.9711

Very volatile

Inventory Turnover

2.26

1.24

1.7457

Pretty Stable

Days Of Inventory On Hand

488

305

345

Pretty Stable

Payables Turnover

0.72

0.76

2.4633

Very volatile

Sales General And Administrative To Revenue

10.46

6.24

7.4548

Very volatile

Research And Ddevelopement To Revenue

17.17

10.22

8.1125

Slightly volatile

Capex To Revenue

0.0809

0.0851

0.6504

Very volatile

Cash Per Share

2.6

2.74

227

Slightly volatile

Days Payables Outstanding

472

497

1.2 K

Slightly volatile

Income Quality

0.95

1.01

0.8731

Pretty Stable

Intangibles To Total Assets

0.019

0.02

0.2035

Slightly volatile

Current Ratio

3.94

5.47

6.4906

Very volatile

Receivables Turnover

1.22

1.29

13.0986

Slightly volatile

Capex Per Share

0.0651

0.0685

11.9021

Slightly volatile

Revenue Per Share

0.18

0.19

463

Slightly volatile

Interest Debt Per Share

0.73

0.76

77.3547

Slightly volatile

Debt To Assets

0.23

0.24

0.1914

Slightly volatile

Graham Number

7.2 K

8.1 K

8.8 K

Slightly volatile

Operating Cycle

278

293

168

Slightly volatile

Days Of Payables Outstanding

472

497

1.2 K

Slightly volatile

Long Term Debt To Capitalization

0.22

0.21

0.2152

Pretty Stable

Quick Ratio

3.93

5.47

6.4875

Very volatile

Net Income Per E B T

0.81

0.91

0.9937

Slightly volatile

Cash Ratio

1.2

1.27

4.8246

Pretty Stable

Days Of Inventory Outstanding

488

305

345

Pretty Stable

Days Of Sales Outstanding

278

293

93.6233

Slightly volatile

Free Cash Flow Operating Cash Flow Ratio

0.83

0.94

1.0422

Pretty Stable

Fixed Asset Turnover

0.37

0.39

73.273

Slightly volatile

Debt Ratio

0.23

0.24

0.1914

Slightly volatile

Price Sales Ratio

33.43

35.19

82.5928

Very volatile

Asset Turnover

0.0597

0.0629

0.4865

Slightly volatile

Abeona Therapeutics Valuation Data

Trends

Current Value

Last Year

Historical Average

10 Year Trend

Market Cap

1.8 M

1.9 M

2.3 M

Slightly volatile

Abeona Fundamental Market Drivers

	Forward Price Earnings	526.3158
	Cash And Short Term Investments	97.7 M

Abeona Upcoming Events

	3rd of April 2024 Upcoming Quarterly Report	View
	9th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	3rd of April 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

About Abeona Therapeutics Financial Statements

Abeona Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Abeona Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Current Deferred Revenue	340.4 K	590.9 K
Cost Of Revenue	3.3 M	3.2 M
Stock Based Compensation To Revenue	1.57	1.49
Sales General And Administrative To Revenue	6.24	10.46
Research And Ddevelopement To Revenue	10.22	17.17
Capex To Revenue	0.09	0.08
Revenue Per Share	0.19	0.18
Ebit Per Revenue	(12.12)	(12.73)

Pair Trading with Abeona Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Abeona Stock

0.64	CMB	Cambium Bio	Pair Corr
0.56	JUMP	Leveljump Healthcare Corp	Pair Corr
0.44	VCEL	Vericel Corp Ord	Pair Corr

The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.

The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock:

How To Invest In Abeona

Details

Is Abeona Stock a good investment?

Details

What is Abeona Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Abeona Therapeutics Correlation against competitors.

To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

1.21

Revenue Per Share

0.008

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.30)

Return On Equity

0.759

The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Abeona Financial Statements From 2010 to 2026

Abeona Therapeutics Total Revenue

3.5 Million

Abeona Therapeutics Balance Sheet

Abeona Therapeutics Income Statement

Abeona Therapeutics Cash Flow Statement

Financial Ratios

Abeona Therapeutics Valuation Data

Abeona Fundamental Market Drivers

Abeona Upcoming Events

About Abeona Therapeutics Financial Statements

Pair Trading with Abeona Therapeutics

Moving against Abeona Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY